Bruker Co. (NASDAQ:BRKR) Holdings Lifted by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. boosted its position in shares of Bruker Co. (NASDAQ:BRKR) by 15.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 466,865 shares of the medical research company’s stock after buying an additional 61,429 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Bruker were worth $43,857,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Lindbrook Capital LLC boosted its stake in Bruker by 68.2% during the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock valued at $26,000 after buying an additional 146 shares in the last quarter. Lifestyle Asset Management Inc. lifted its holdings in shares of Bruker by 1.3% during the first quarter. Lifestyle Asset Management Inc. now owns 12,534 shares of the medical research company’s stock valued at $1,177,000 after purchasing an additional 158 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Bruker by 19.4% during the first quarter. Park Place Capital Corp now owns 1,139 shares of the medical research company’s stock valued at $107,000 after purchasing an additional 185 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of Bruker by 24.7% during the fourth quarter. Assetmark Inc. now owns 1,005 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 199 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Bruker by 139.1% during the first quarter. Covestor Ltd now owns 361 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 210 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Up 4.0 %

Shares of BRKR traded up $2.58 during midday trading on Friday, reaching $66.81. 1,233,947 shares of the stock were exchanged, compared to its average volume of 966,267. Bruker Co. has a 12-month low of $53.79 and a 12-month high of $94.86. The firm has a 50 day simple moving average of $66.08 and a 200-day simple moving average of $76.06. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. The company has a market cap of $9.71 billion, a price-to-earnings ratio of 24.29, a P/E/G ratio of 2.33 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The company had revenue of $721.70 million during the quarter, compared to the consensus estimate of $729.88 million. During the same period last year, the business earned $0.64 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Research analysts forecast that Bruker Co. will post 2.66 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 17th. Stockholders of record on Monday, June 3rd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend was Monday, June 3rd. Bruker’s dividend payout ratio is 7.27%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BRKR. Jefferies Financial Group began coverage on Bruker in a report on Monday, June 3rd. They set a “buy” rating and a $85.00 target price for the company. Stifel Nicolaus reduced their target price on Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a report on Monday, May 20th. Citigroup reduced their target price on Bruker from $95.00 to $80.00 and set a “buy” rating for the company in a report on Wednesday, July 10th. StockNews.com downgraded Bruker from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. Finally, Bank of America reduced their price objective on Bruker from $95.00 to $90.00 and set a “buy” rating for the company in a research note on Monday, May 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Bruker presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.78.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.